23 May 2013
Keywords: strong, preclinical, data, aeterna, cancer, drug, drugmaker
Article | 05 February 2007
US drugmaker AEterna Zentaris presented strong in vivo data on ZEN-012, its novel, oral anticancer compound, at the 7th Joint ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 February 2007
22 May 2013
© 2013 thepharmaletter.com